Equities Analysts Offer Predictions for ORIC Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Oric Pharmaceuticals to ($0.38) per share, reflecting an improvement from a previous estimate of ($0.46).
• The company's stock currently holds an average rating of "Moderate Buy" with a consensus price target of $17.63.
• Oric Pharmaceuticals' shares have recently seen significant institutional investment, with 95.05% of the stock owned by institutional investors.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Equities researchers at HC Wainwright upped their Q3 2025 earnings estimates for shares of Oric Pharmaceuticals in a report issued on Thursday, August 14th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their previous estimate of ($0.46). HC Wainwright has a "Buy" rating and a $19.00 price target on the stock. The consensus estimate for Oric Pharmaceuticals' current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals' Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.60) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.51) EPS.

Several other brokerages have also recently weighed in on ORIC. Zacks Research upgraded Oric Pharmaceuticals to a "hold" rating in a research note on Tuesday, August 12th. JPMorgan Chase & Co. dropped their price objective on Oric Pharmaceuticals from $20.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday. Wedbush restated an "outperform" rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. Cantor Fitzgerald restated an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Guggenheim restated a "buy" rating and set a $18.00 price objective on shares of Oric Pharmaceuticals in a research note on Wednesday, August 13th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $17.63.

Oric Pharmaceuticals Trading Down 2.7%

Shares of NASDAQ:ORIC opened at $9.66 on Monday. The stock's fifty day simple moving average is $10.30 and its two-hundred day simple moving average is $8.06. Oric Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $14.67. The stock has a market cap of $938.18 million, a PE ratio of -5.11 and a beta of 1.69.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01).

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its stake in shares of Oric Pharmaceuticals by 1,293.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,757 shares of the company's stock worth $119,000 after purchasing an additional 10,913 shares during the period. Eventide Asset Management LLC bought a new stake in Oric Pharmaceuticals in the 2nd quarter valued at about $9,657,000. BNP Paribas Financial Markets raised its stake in Oric Pharmaceuticals by 1,102.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 86,755 shares of the company's stock valued at $881,000 after acquiring an additional 79,540 shares during the period. Brevan Howard Capital Management LP bought a new stake in Oric Pharmaceuticals in the 2nd quarter valued at about $352,000. Finally, Bank of America Corp DE raised its stake in Oric Pharmaceuticals by 14.9% in the 2nd quarter. Bank of America Corp DE now owns 298,442 shares of the company's stock valued at $3,029,000 after acquiring an additional 38,641 shares during the period. 95.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Oric Pharmaceuticals news, Director Angie You bought 26,597 shares of the stock in a transaction dated Friday, June 20th. The shares were bought at an average cost of $9.39 per share, for a total transaction of $249,745.83. Following the purchase, the director directly owned 26,597 shares of the company's stock, valued at approximately $249,745.83. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Dominic Piscitelli sold 32,466 shares of Oric Pharmaceuticals stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total value of $340,893.00. Following the sale, the chief financial officer owned 68,317 shares in the company, valued at $717,328.50. The trade was a 32.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock worth $416,289 over the last quarter. Company insiders own 5.55% of the company's stock.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.